— All Articles —
The latest from The Peptide Brief.
Retatrutide vs Mounjaro: What the Latest Trial Data Really Shows — and What It Doesn’t
Results emerging from retatrutide’s clinical development programme have generated significant excitement, with some reports suggesting the drug could outperform tirzepatide…
Alluvi Healthcare Retatrutide Investigation: £200,000 Frozen in UK Weight-Loss Jab Probe
More than £200,000 held across three bank accounts has been frozen as part of an ongoing Medicines and Healthcare products…
Three Million UK Adults Now Use Weight Loss Jabs — And Supermarkets Are Paying Attention
Three million UK adults are now estimated to use GLP-1 medicines, according to new analysis from PwC — a figure…
GLP-1 Drugs and Alcohol: Why Researchers Are Taking the Evidence More Seriously
For several years, people taking weight-loss medicines such as semaglutide (Ozempic, Wegovy) have been reporting something unexpected: they seem to…
Retatrutide vs Mounjaro: How Do the Two Eli Lilly Weight Loss Jabs Actually Compare?
If you have been following the weight loss medicine story closely, you will have noticed that retatrutide and Mounjaro keep…
Retatrutide and the Fitness Community: What the ‘New Steroids’ Warning Actually Means
A comparison that would have seemed far-fetched a few years ago is now being made with increasing seriousness by doctors:…
Eli Lilly Sues Six Companies Over Unlicensed Retatrutide Sales — What UK Users Need to Know
Eli Lilly, the pharmaceutical company developing retatrutide, has filed a lawsuit in a US federal court against six companies it…
Retatrutide Early Access Is Now Open in the US – But UK Patients Are Not Eligible Yet
Retatrutide has been one of the most talked-about medicines in weight loss research for the past two years. This week,…
Six Cases of Liver Damage Linked to Grey Market Retatrutide: What UK Patients Need to Know
Grey market retatrutide is at the centre of a serious and urgent conversation across weight loss medication communities this week…